Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
Memorial Sloan Kettering Cancer Center · University College London · +26 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
300
total citations
- FWCI
- 41.70
- Percentile
- 100%
- References
- 33
Citations per year
Authors
19- RJRobert J. MotzerCorresponding
Memorial Sloan Kettering Cancer Center
- TPThomas Powles
University College London, National Health Service, Cancer Research UK, The Royal Free Hospital, Queen Mary University of London
- MBMauricio Burotto
- BEBernard Escudier
Institut Gustave Roussy
- MTMaría T. Bourlon
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Topics & keywords
Topics
Keywords
- Cabozantinib
- Sunitinib
- Medicine
- Nivolumab
- Renal cell carcinoma
- Clinical endpoint
- Internal medicine
- Kidney cancer
No related works found for this paper.